Pancreatic Cancer Clinical Trials
Pancreatic Cancer
Learn More About Pancreatic Cancer
For general information on pancreatic cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| BI - 1456-0001 | Pancreatic Cancer | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Immunotherapy | Genetically Modified Virus | Open - Recruiting | Boehringer Ingelheim | NCT05155332 | Enquire Now |
| ADCE-T02-01 | Pancreatic Cancer | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| SL-28-FIH | Pancreatic Cancer | A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours | Immunotherapy | IV allogeneic, non-genetically modified cell-based therapy | Open - Recruiting | Second Life Therapeutics Pty Ltd. | ACTRN12625001342404p | Enquire Now |